Adagene, Inc. (ADAG)
NASDAQ:ADAG
Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.97
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.97
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.75
Previous CloseN/A
Volume1.51K
Average Volume (3M)146.48K
Market Cap
$186.70M
Enterprise Value$64.64M
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Sep 02, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume163,526
30 Day Avg. Volume146,484
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue8.40
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda-3.09
Forecast
1Y Price Target
$8.33Price Target Upside109.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Compelling Clinical EfficacyStrong, reproducible response rates and manageable safety across multiple Phase 1b/2 cohorts materially derisk muzastotug as a backbone immuno‑oncology agent. Durable efficacy signals in hard‑to‑treat HCC and MSS colorectal cancer support a registrational path and long‑term commercial opportunity in combination regimens.
Strategic PartnershipsMultiple collaborations validate the platform, spread R&D risk, and provide non‑dilutive milestone and service revenue. Partner involvement increases resources for late‑stage development, accelerates access to complementary assets, and enhances commercialization pathways if clinical readouts remain positive.
Improved Funding And RunwayMaterial cash on hand, recent $70M offering, and stated runway into early 2028 reduce near‑term financing pressure and allow execution of randomized dose‑optimization and registrational trials. Manageable leverage improvement further supports continuity of clinical programs without immediate fundraising.
Bears Say
Chronic Cash BurnPersistent negative operating and free cash flow means the company remains reliant on external financing to fund operations and trials. Even with better 2025 metrics, multi‑year cash burn raises dilution and execution risk if clinical timelines slip or milestone receipts are delayed.
Volatile, Milestone‑driven RevenueRevenue is driven by uneven collaboration milestones rather than recurring product sales, producing large year‑to‑year swings and occasional negative gross profit. This revenue instability complicates planning, increases dependency on unpredictable partner milestones, and limits durable internal funding capacity.
Ongoing Losses And Weak ReturnsThe company has not achieved profitability and shows negative returns on capital, indicating current R&D investment has yet to translate into shareholder returns. Historical equity deficit and ongoing losses create dilution risk and mean value realization depends heavily on future positive trial outcomes and successful commercialization.
Adagene News
ADAG FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was $1.30 and its highest was $4.75 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is $186.70M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 73 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (109.91% Upside)
$8.33 (109.91% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.05%
12-Months-Change
Fundamentals
Return on Equity
-48.20%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$8.33
▲(109.91% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---